Meinong Bio disclosed its 2026 half-year report on the evening of August 26. In the first half, it achieved operating revenue of 328 million yuan, up 38.71% year on year. Net profit attributable to the parent company was 18.061 million yuan, down 23.23% year on year. Excluding the impact of share-based payments, net profit rose 7.55% year on year. The revenue growth was mainly driven by a surge in overseas markets. Overseas revenue reached 164 million yuan, up 81.01% year on year, while domestic revenue was 164 million yuan, up 12.39% year on year. The share of overseas revenue rose to 50%. The company mainly produces feed additives and enzymatically hydrolyzed protein feed ingredients, covering pig, ruminant, poultry, and aquaculture farming sectors. Its international business now spans more than 40 countries and regions. The company is also deepening its presence in the domestic market by focusing on core products, with gut health products achieving growth of more than 30% in the domestic market.
Shanghai Menon Animal Nutrition Technology Co. Ltd.Overseas revenue surged 81% and domestic gut health products grew over 30%, driving overall revenue up 38.71%.
